JMIR Cancer

Cancer survivors frequently face persistent nutrition-related challenges after treatment. Mobile health tools may extend access to dietary self-management support beyond clinic settings, but feasibility and preliminary effects remain insufficiently characterized in this population.

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that requires rapid diagnosis and intervention. However, identifying these patients is difficult because the HLH-2004 diagnostic criteria are complex and not always captured systematically in electronic health records (EHRs). Furthermore, it is unclear how clinicians use these criteria to diagnose HLH and make treatment decisions. There is a critical need for validated computable phenotypes to accurately identify patients and study treatment-related outcomes in HLH.

Melanoma, a highly aggressive form of skin cancer, is the second most common type of cancer for adolescent and young adult (AYA, ages 15-39 years) patients. AYA patients with melanoma may turn to internet sources, especially artificial intelligence (AI) chatbots, to manage uncertainty about prognosis and treatment.

Published evidence on patient experiences, perceptions, and challenges related to early breast cancer (eBC) in Italy is limited. Understanding these aspects is critical for improving diagnosis, treatment outcomes, and quality of life (QoL).

Mediastinal germ cell tumors and how they differ from those associated with testicular cancer are reviewed through the experience with my son, Brendan Fahy Bequette. We reflect on others who have been diagnosed with rare tumors and discuss our need to honor Brendan’s memory by “paying it forward.”

Electronic patient-reported outcome tools have the potential to enhance supportive care in oncology and support the timely and accurate identification of patients’ needs.

Technology is changing the way the world communicates and how we learn, remember, and transform information. The ascendancy of the internet has dramatically altered the landscape of health information access and seeking behaviors. This transformation is embodied by the concept of digital health literacy (DHL) and the need for interventions that improve DHL.

Patients with metastatic breast cancer (MBC) experience significant quality-of-life decrements, but there are few supportive care interventions specifically designed for this group that significantly improve quality of life. Ecological momentary assessment (EMA) and related ecological momentary interventions (EMIs) may be particularly beneficial for patients with MBC. However, no studies have previously examined the use of EMIs in the context of metastatic cancer.

To support physicians in focusing on relevant information during melanoma treatment, it is essential to design information systems (ISs) that integrate into their workflow.

Artificial intelligence (AI) is increasingly used to generate medical content, yet its performance in delivering clinically relevant and reliable information remains underexplored, especially in complex areas such as breast cancer.

Adolescents and young adults with cancer have distinct developmental and psychosocial needs that require care models bridging pediatric and adult oncology systems. While survival outcomes have improved, there is growing recognition of the need to strengthen coordinated care, psychosocial support, and survivorship services. In Ontario, regional and community-based cancer programs play a central role in delivering accessible care and are well-positioned to support adolescents and young adults closer to home. However, variation in infrastructure, workforce capacity, and system-level coordination influences how developmentally appropriate oncology care is implemented. Existing literature has focused on tertiary and specialty centers, highlighting the need to leverage and strengthen regional systems, providers, and community resources to support high-quality adolescent and young adult cancer care.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their safety profile in patients with thymic epithelial tumors (TETs) remains poorly characterized due to the rarity of these malignancies.